Expanded indication 6-11 years
DUPIXENT is a biologic with a novel mechanism of action to
treat uncontrolled moderate-to-severe atopic dermatitis
in patients aged 6 years and older1
Consider referring to a
DERMATOLOGIST or ALLERGIST
DERMATOLOGIST or ALLERGIST
today to see what’s
possible with DUPIXENT
possible with DUPIXENT
When topical Rx therapies aren’t enough, DUPIXENT may be appropriate
Patients may be appropriate for DUPIXENT if they:
- Have tried a variety of topical Rx therapies and are still uncontrolled
- Suffer from inadequate control of pruritus
- Have ≥10% of their body covered with lesions and/or may involve problem areas such as the face, hands, and feet
- Have moderate-to-severe erythema and moderate-to-severe papulation/infiltration (IGA score of 3=moderate or 4=severe)
Consider referring your patients to a specialist today
Partner with an eczema specialist to help your patients. Use the HealthgradesTM tool to easily find nearby eczema specialists with experience in treating children (aged 6 to 11 years), adolescents (aged 12 to 17 years), and adults (aged 18+ years) with uncontrolled moderate-to-severe atopic dermatitis.
Unlike topical and oral corticosteroids, DUPIXENT
targets a source of underlying inflammation to proactively treat AD1,2
Atopic dermatitis is a chronic, recurring, and systemic disease, leaving patients trapped
in an endless cycle of flares driven in part by persistent underlying inflammation2,3
DUPIXENT Is Revolutionizing
Atopic Dermatitis
Atopic Dermatitis
DUPIXENT has proven efficacy and demonstrated long-term safety profile in moderate-to-severe atopic dermatitis uncontrolled with topical Rx therapy1
Itch relief1
Clear or almost-clear skin and improvement
in lesion extent and severity1
Clinical trial outcomes
supported by real-world data in adults1,6,7
Demonstrated safety profile1
DUPIXENT is not an
immunosuppressant1
There is no requirement for initial lab testing or ongoing lab monitoring according to the Prescribing Information1
The most common adverse reactions (incidence ≥1% at Week 16) in adult patients with atopic dermatitis were injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, and dry eye. The safety profile in children and adolescents through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT in adolescents and children observed through Week 52 was consistent with that seen in adults with atopic dermatitis.1
Trial Designs and Results
A total of 917 adults in Trials 1 and 2, 251 adolescents in Trial 6, 367 children (6-11 years of age) in Trial 8 (16 weeks each), and 421 adults in Trial 3 (52 weeks) with moderate-to-severe atopic dermatitis inadequately controlled with topical prescription therapies were randomized to DUPIXENT or placebo. All patients in Trials 3 and 8 received concomitant TCS. All adults and adolescents ≥60 kg received 300 mg Q2W after a 600 mg loading dose. Adolescents <60 kg and children ≥30 kg but <60 kg received 200 mg Q2W after a 400 mg loading dose. Children 15 kg but <30 kg received 300 mg Q4W after a 600 mg loading dose.1
In Trials 1, 2, 3, and 6, patients had moderate-to-severe disease, with an IGA score ≥3 (overall lesion severity scale of 0 to 4), an EASI score ≥16 on a scale of 0 to 72, and BSA involvement ≥10%. In Trial 8, patients had an IGA score of 4 (severe), an EASI score ≥21, and BSA involvement ≥15%. At baseline, 52% of adults and 46% of adolescents had an IGA score of 3 (moderate), 48% of adults and 54% of adolescents had an IGA of 4 (severe); mean EASI score was 33 for adults, 36 for adolescents, and 37.9 for children; weekly averaged Peak Pruritus NRS was 7 for adults, 8 for adolescents, and 7.8 for children, on a scale of 0 to 10.1
The primary endpoint in Trials 1, 2, 3, and 6 was change from baseline in the proportion of subjects with an IGA 0 (clear) or 1 (almost clear) and ≥2-point improvement at Week 16 (38% and 36% of adults treated with DUPIXENT vs 10% and 9% with placebo in Trials 1 and 2, respectively, P<0.001; 39% of adults treated with DUPIXENT + TCS vs 12% with placebo + TCS in Trial 3, P<0.0001; and 24% of adolescents treated with DUPIXENT vs 2% with placebo in Trial 6, P<0.001). In Trial 8, the primary endpoint was change from baseline in the proportion of subjects with an IGA 0 or 1 at Week 16 (39% of children ≥30 kg treated with DUPIXENT + TCS vs 10% with placebo + TCS, and 30% of children <30 kg treated with DUPIXENT + TCS vs 13% with placebo + TCS).1,8-11
Other endpoints included change from baseline in the proportion of subjects with EASI-75 at Week 16 (improvement of ≥75%; 51% and 44% of adults treated with DUPIXENT vs 15% and 12% with placebo in Trials 1 and 2, respectively, P<0.001; 69% of adults treated with DUPIXENT + TCS vs 23% with placebo + TCS in Trial 3, P<0.0001; 42% of adolescents treated with DUPIXENT vs 8% with placebo in Trial 6, P<0.001; 75% of children ≥30 kg treated with DUPIXENT + TCS vs 26% with placebo + TCS, and 75% of children <30 kg treated with DUPIXENT + TCS vs 28% with placebo + TCS in Trial 8; and itch reduction defined by ≥4-point improvement in the Peak Pruritus NRS at Week 16 (41% and 36% of adults treated with DUPIXENT vs 12% and 10% with placebo in Trials 1 and 2, respectively, P<0.001; 59% of adults treated with DUPIXENT + TCS vs 20% with placebo + TCS in Trial 3, P<0.0001; 37% of adolescents treated with DUPIXENT vs 5% with placebo in Trial 6, P<0.001; 61% of children ≥30 kg treated with DUPIXENT + TCS vs 13% with placebo + TCS; and 54% of children <30 kg treated with DUPIXENT + TCS vs 12% with placebo + TCS in Trial 8).1,8-11
BSA, body surface area; EASI, Eczema Area and Severity Index; IGA, Investigator’s Global Assessment; NRS, numerical rating scale; Q2W, once every 2 weeks; Q4W, once every 4 weeks; TCS, topical corticosteroids.